Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Identification of a Somatic Mutation-Derived Long Non-Coding RNA Signatures of Genomic Instability in Renal Cell Carcinoma.

Tytuł:
Identification of a Somatic Mutation-Derived Long Non-Coding RNA Signatures of Genomic Instability in Renal Cell Carcinoma.
Autorzy:
Fang X; Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.; Department of Medical Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China.
Liu X; Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.; Department of Medical Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China.
Lu L; Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.; Department of Medical Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China.
Liu G; Department of Medical Oncology, Guangzhou First People's Hospital, School of Medicine, South China University of Technology, Guangzhou, China.; Department of Medical Oncology, Guangzhou First People's Hospital, Guangzhou Medical University, Guangzhou, China.
Źródło:
Frontiers in oncology [Front Oncol] 2021 Oct 05; Vol. 11, pp. 728181. Date of Electronic Publication: 2021 Oct 05 (Print Publication: 2021).
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: [Lausanne : Frontiers Research Foundation]
References:
Mol Ther Nucleic Acids. 2018 Sep 7;12:684-697. (PMID: 30092404)
CA Cancer J Clin. 2019 Jan;69(1):7-34. (PMID: 30620402)
Urologe A. 2009 Jun;48(6):625-7. (PMID: 19300979)
Clin Epigenetics. 2021 May 4;13(1):103. (PMID: 33947447)
Gene. 2018 Jan 10;639:77-84. (PMID: 28987345)
Genes (Basel). 2019 May 28;10(6):. (PMID: 31142004)
Respir Med Case Rep. 2021 Mar 19;33:101388. (PMID: 33854938)
Int J Biochem Cell Biol. 2018 Oct;103:125-134. (PMID: 30142387)
Biosci Rep. 2017 Oct 17;37(5):. (PMID: 28939763)
Front Mol Biosci. 2021 Mar 25;8:623120. (PMID: 33842538)
DNA Cell Biol. 2019 Feb;38(2):176-183. (PMID: 30601026)
Cell. 2019 Jan 24;176(3):505-519.e22. (PMID: 30612738)
Front Oncol. 2019 Oct 18;9:1048. (PMID: 31681586)
Mol Cell Biochem. 2021 Jun;476(6):2365-2379. (PMID: 33591455)
Clin Cancer Res. 2004 Aug 15;10(16):5464-71. (PMID: 15328185)
Gene. 2019 Feb 15;685:76-84. (PMID: 30359741)
Oncotarget. 2018 Jan 8;9(15):12101-12111. (PMID: 29552295)
Cell Death Differ. 2017 Sep;24(9):1502-1517. (PMID: 28644440)
Cell. 2016 Jan 14;164(1-2):69-80. (PMID: 26724866)
Aging (Albany NY). 2020 Jul 27;12(15):15359-15373. (PMID: 32716909)
Nat Cell Biol. 2021 Apr;23(4):295-296. (PMID: 33837286)
Am J Physiol Cell Physiol. 2021 May 1;320(5):C880-C891. (PMID: 33502949)
Cancer J. 2014 Jul-Aug;20(4):272-80. (PMID: 25098288)
J Urol. 2005 May;173(5):1496-501. (PMID: 15821467)
Postgrad Med J. 2020 May;96(1135):286-295. (PMID: 32054779)
Proc Natl Acad Sci U S A. 2004 Dec 7;101(49):17174-9. (PMID: 15569934)
Front Cell Dev Biol. 2021 Mar 29;9:657667. (PMID: 33855028)
Urology. 2001 Aug;58(2):141-5. (PMID: 11489682)
Cancer Manag Res. 2019 Feb 22;11:1779-1789. (PMID: 30863183)
Clin Cancer Res. 2021 Jun 15;27(12):3491-3498. (PMID: 33795256)
Cancer Cell Int. 2020 May 13;20:166. (PMID: 32435157)
BJU Int. 2021 Sep;128(3):386-394. (PMID: 33794055)
Eur Rev Med Pharmacol Sci. 2018 Feb;22(4):1003-1010. (PMID: 29509248)
Clin Genitourin Cancer. 2006 Dec;5(3):206-11. (PMID: 17239274)
Int J Med Sci. 2021 Jan 1;18(4):953-963. (PMID: 33456353)
Cancer Lett. 2018 Apr 28;420:80-90. (PMID: 29409808)
Oncologist. 2021 May;26(5):e905-e906. (PMID: 33650184)
Nature. 2020 Feb;578(7793):94-101. (PMID: 32025018)
J Carcinog Mutagen. 2014;5:. (PMID: 25541596)
Bioengineered. 2021 Dec;12(1):1725-1738. (PMID: 33955803)
Nat Rev Urol. 2019 Aug;16(8):484-504. (PMID: 31110275)
Cell. 2018 Aug 9;174(4):1034-1035. (PMID: 30096302)
J Hematol Oncol. 2021 Mar 19;14(1):46. (PMID: 33741027)
J Cancer. 2018 Jul 16;9(16):2834-2843. (PMID: 30123352)
BJU Int. 2003 Dec;92(9):901-5. (PMID: 14632843)
Front Cell Dev Biol. 2021 Mar 19;9:618987. (PMID: 33816467)
Eur Rev Med Pharmacol Sci. 2021 Mar;25(5):2235-2244. (PMID: 33755961)
Respirology. 2011 Jul;16(5):796-802. (PMID: 21435097)
Front Oncol. 2021 Mar 30;11:617383. (PMID: 33859936)
Cancers (Basel). 2021 Feb 18;13(4):. (PMID: 33670609)
Urol Oncol. 2021 Feb;39(2):135.e1-135.e8. (PMID: 33309297)
Cancers (Basel). 2021 Mar 16;13(6):. (PMID: 33809567)
Nat Rev Cancer. 2020 Oct;20(10):555-572. (PMID: 32778778)
Annu Rev Genet. 2013;47:1-32. (PMID: 23909437)
Int J Urol. 2009 Jul;16(7):616-21. (PMID: 19456988)
Toxicology. 2017 Nov 1;391:75-83. (PMID: 28756246)
EBioMedicine. 2015 Sep 08;2(11):1814-20. (PMID: 26870806)
Cancers (Basel). 2021 Mar 12;13(6):. (PMID: 33809306)
Front Oncol. 2021 Feb 22;11:607595. (PMID: 33692951)
Transl Gastroenterol Hepatol. 2018 Jun 29;3:36. (PMID: 30050996)
Contributed Indexing:
Keywords: genome instability-related lncRNAs (GInLncRNAs); genomic instability; lncRNA; prognostic risk model; renal cell carcinoma
Entry Date(s):
Date Created: 20211022 Latest Revision: 20220427
Update Code:
20240105
PubMed Central ID:
PMC8523920
DOI:
10.3389/fonc.2021.728181
PMID:
34676164
Czasopismo naukowe
Background: Renal cell carcinoma (RCC) is a malignant tumor with high morbidity and mortality. It is characterized by a large number of somatic mutations and genomic instability. Long non-coding RNAs (lncRNAs) are widely involved in the expression of genomic instability in renal cell carcinoma. But no studies have identified the genome instability-related lncRNAs (GInLncRNAs) and their clinical significances in RCC.
Methods: Clinical data, gene expression data and mutation data of 943 RCC patients were downloaded from The Cancer Genome Atlas (TCGA) database. Based on the mutation data and lncRNA expression data, GInLncRNAs were screened out. Co-expression analysis, Gene Ontology (GO) enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis were conducted to explore their potential functions and related signaling pathways. A prognosis model was further constructed based on genome instability-related lncRNAs signature (GInLncSig). And the efficiency of the model was verified by receiver operating characteristic (ROC) curve. The relationships between the model and clinical information, prognosis, mutation number and gene expression were analyzed using correlation prognostic analysis. Finally, the prognostic model was verified in clinical stratification according to TCGA dataset.
Results: A total of 45 GInLncRNAs were screened out. Functional analysis showed that the functional genes of these GInLncRNAs were mainly enriched in chromosome and nucleoplasmic components, DNA binding in molecular function, transcription and complex anabolism in biological processes. Univariate and Multivariate Cox analyses further screened out 11 GInLncSig to construct a prognostic model (AL031123.1, AC114803.1, AC103563.7, AL031710.1, LINC00460, AC156455.1, AC015977.2, 'PRDM16-dt', AL139351.1, AL035661.1 and LINC01606), and the coefficient of each GInLncSig in the model was calculated. The area under the curve (AUC) value of the ROC curve was 0.770. Independent analysis of the model showed that the GInLncSig model was significantly correlated with the RCC patients' overall survival. Furthermore, the GInLncSig model still had prognostic value in different subgroups of RCC patients.
Conclusion: Our study preliminarily explored the relationship between genomic instability, lncRNA and clinical characteristics of RCC patients, and constructed a GInLncSig model consisted of 11 GInLncSig to predict the prognosis of patients with RCC. At the same time, our study provided theoretical support for the exploration of the formation and development of RCC.
Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
(Copyright © 2021 Fang, Liu, Lu and Liu.)

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies